Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medclair ABNGM:MCLR -2.24%70 ROC (Joel Greenblatt) % is 191.33% as of Mar. 2026. GuruFocus rates NGM:MCLR with a GF Score™ of 70/100 and a GF Value™ of kr2.35 (Modestly Overvalued). Among 840 Medical Devices & Instruments companies, Medclair AB ranks better than 91.07% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Medclair AB's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 191.33%.
The historical rank and industry rank for Medclair AB's ROC (Joel Greenblatt) % or its related term are showing as below:
NGM:MCLR'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1488.35 Med: -119.72 Max: 63.09
Current: 56.53
During the past 11 years, Medclair AB's highest ROC (Joel Greenblatt) % was 63.09%. The lowest was -1488.35%. And the median was -119.72%.
NGM:MCLR's ROC (Joel Greenblatt) % is ranked better than 91.07% of 840
companies
in the Medical Devices & Instruments industry
Industry Median: 4.145
vs NGM:MCLR: 56.53
Medclair AB's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.
Medclair AB (NGM:MCLR) ROC (Joel Greenblatt) % Explanation
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
Medclair AB ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Medclair AB's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NGM:MCLR vs ABT, SYK, MDT: ROC (Joel Greenblatt) % Comparison
For the Medical Devices subindustry, Medclair AB's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medclair AB ROC (Joel Greenblatt) % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Medclair AB's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Medclair AB's ROC (Joel Greenblatt) % falls into.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 191.33% mean?
Medclair AB (NGM:MCLR) has a ROC (Joel Greenblatt) % of 191.33% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Medclair AB and its competitors. According to the industry distribution chart, Medclair AB ranks #75 out of 840 companies in the Medical Devices & Instruments industry, placing it in the top 8.9%.
Is Medclair AB's ROC (Joel Greenblatt) % too high?
Medclair AB's current ROC (Joel Greenblatt) % is 191.33%. The Medical Devices & Instruments industry median ROC (Joel Greenblatt) % is 4.15. Medclair AB's value of 191.33% is 4515.9% above this industry median. Based on the distribution chart, Medclair AB ranks #75 out of 840 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Medclair AB has a GF Score™ of 70/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medclair AB's ROC (Joel Greenblatt) % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Medclair AB ranks #75 out of 840 companies for ROC (Joel Greenblatt) %. This places Medclair AB in the top 9% of its industry — outperforming the majority of peers. The industry median ROC (Joel Greenblatt) % is 4.15. Medclair AB's value of 191.33% is 4515.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Medical Devices & Instruments company?
The median ROC (Joel Greenblatt) % among Medical Devices & Instruments companies is 4.15, based on 840 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medclair AB's current ROC (Joel Greenblatt) % of 191.33% is 4515.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Medclair AB and its competitors. For the Medical Devices & Instruments industry, the median ROC (Joel Greenblatt) % is 4.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medclair AB's current ROC (Joel Greenblatt) % is 191.33%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medclair AB stock overvalued right now?
Based on GuruFocus' analysis, Medclair AB (NGM:MCLR) is currently considered Modestly Overvalued. The stock's GF Value™ is kr2.35, compared to a current price of kr3.05 — trading 29.8% above its estimated fair value. The current ROC (Joel Greenblatt) % is 191.33% and 4515.9% above the Medical Devices & Instruments industry median of 4.15. Medclair AB's overall GF Score™ is 70/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Medclair AB (NGM:MCLR), the current ROC (Joel Greenblatt) % is 191.33% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medclair AB (NGM:MCLR) Overvalued in 2026?
Based on GuruFocus' analysis, Medclair AB stock appears to be overvalued.
The current stock price of kr3.05 is trading 29.8% above its estimated GF Value™ of kr2.35.
GuruFocus considers Medclair AB to be Modestly Overvalued.
Key valuation signals for NGM:MCLR:
ROC (Joel Greenblatt) %: 191.33%
GF Value™: kr2.35 vs. price of kr3.05 (29.8% above fair value)
Industry Position: 4515.9% above the Medical Devices & Instruments median (#75 of 840)
No single metric tells the full story. See the NGM:MCLR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medclair AB operates in healthcare industry. The company has two units: Central Destruction Unit (CDU) and Mobile Destruction Unit (MDU) decomposes the nitrous oxide entering the unit, transforming it to nitrogen (N2) och oxygen (O2). It also provide solutions for various N2O methods such as double mask, single mask, mouthpiece, or free flow, which ensures a safe work environment for healthcare professionals.
70GF Score
Get the complete analysis for NGM:MCLR
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NGM:MCLR has been successfully added to your 
